

[REDACTED]  
Allergan  
1<sup>st</sup> Floor Marlow International  
Parkway  
Marlow  
Buckinghamshire  
SL7 1YL

11 March 2011

National Institute for Health and Clinical Excellence  
Level 1A, City Tower  
Piccadilly Plaza  
Manchester  
M1 4BD

**Re: Single Technology Appraisal: Dexamethasone intravitreal implant for the treatment of macular oedema caused by retinal vein occlusion (RVO)**

Dear Lori,

Further to the Appraisal Consultation Document issued 1<sup>st</sup> February 2011 please find attached the following information:

- A detailed response to the additional analyses requested by the NICE Appraisal Committee (core document and appendices)
- A brief summary to address other detailed points highlighted within the Appraisal Consultation Document in response to the structured questions provided by NICE
- A revised basecase economic model for OZURDEX (dexamethasone intravitreal implant) compared to standard of care (observation)
- A new economic model providing an exploratory scenario analysis permitting comparison between OZURDEX (dexamethasone intravitreal implant) and anti-VEGF treatments occasionally used in NHS practice
- Brief user notes to support ERG review of the 2 economic models provided

As agreed at our meeting on Tuesday, the following elements will follow by 5pm on Friday 18<sup>th</sup> March:

- Confidential checklist to cover all new information provided
- Redacted model versions with confidential information removed

Whilst all elements of the analyses enclosed have been subject to considerable scrutiny in review, if we identify any outstanding issues we would like to agree that these can be shared with you as amendments, ultimately to support the ERG review process. Please could you confirm that this would be acceptable.

If you require any further information at this time, please don't hesitate to contact me to discuss.

Yours sincerely,

[REDACTED]  
Allergan, EAME